http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6455183-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c999fee6428152a996011d506925c2d7 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate | 1987-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de2e61de6fd98374d109abde7eab31b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb7ffd133db56882bdf0f3dedb785b9c |
| publicationDate | 1989-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S6455183-A |
| titleOfInvention | Production of antitumor active substance |
| abstract | PURPOSE:To mass-produce a vascular endothelial cell growth inhibitory factor with hardly any side effects, by cultivating a cellular strain derived from human chondrosarcoma in a specific culture medium. CONSTITUTION:Tissues collected from human chondrosarcoma are treated with trypsin to separate human chondrosarcoma-derived cellular strain (HCS) and provide individual cells, which are then inoculated into an MEM culture medium containing 20% FCS, etc., and subcultured at 37 deg.C while exchanging the culture medium every 2-4 days to afford the aimed HCS cells capable of exhibiting stable growth. 1-2X10<7> resultant cells are subsequently seeded onto a 800cm<2> plate and cultivated in Dulbecco's MEM culture medium containing 10% FCS added thereto for 3-4 weeks and then in serum-free Dulbecco's MEM culture medium for 48hr to recover the obtained culture fluid and provide a cultivation supernatant sample, which is subsequently dissolved in an aqueous solution of a salt, such as guanidine, at pH5-7. The obtained solution is then subjected to fractionation treatment with a membrane to afford the aimed vascular endothelial cell growth inhibitory factor contained in a fraction having >=10,000 molecular weight. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H04226274-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5524427-A |
| priorityDate | 1987-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.